| Literature DB >> 32681867 |
Aljoša Stanković1, Jasna Mihailović2, Marija Mirković3, Magdalena Radović3, Zorana Milanović3, Miloš Ognjanović3, Drina Janković3, Bratislav Antić3, Milica Mijović4, Sanja Vranješ-Đurić3, Željko Prijović3.
Abstract
Combined radionuclide therapy with magnetic nanoparticles-mediated hyperthermia has been under research focus as a promising tumor therapy approach. The objective of this study was to investigate the potential of 131I-radiolabeled superparamagnetic iron oxide nanoparticles (SPIONs) prepared as the ~40 nm flower-shaped structures with excellent heating efficiency (specific absorption rate at H0 = 15.9 kA∙m-1 and resonant frequency of 252 kHz was 123.1 W∙g-1) for nano-brachytherapy of tumors. 131I-radiolabeled CC49 antibody attached to SPIONs via reactive groups of 3-aminopropyltriethoxysilane (APTES) provided specificity and long-lasting localized retention after their intratumoral application into LS174T human colon adenocarcinoma xenografts in NOD-SCID mice. The results demonstrate feasibility and effectiveness of magnetic hyperthermia (HT), radionuclide therapy (RT) and their combination (HT + RT) in treating cancer in xenograft models. Combined therapy approach induced a significant (p < 0.01) tumor growth suppression in comparison to untreated groups presented by the tumor volume inhibitory rate (TVIR): 54.38%, 68.77%, 73.00% for HT, RT and HT + RT, respectively in comparison to untreated group and 48.31%, 64,62% and 69,41%, respectively, for the SPIONs-only injected group. Histopathology analysis proved the necrosis and apoptosis in treated tumors without general toxicity. Obtained data support the idea that nano-brachytherapy combined with hyperthermia is a promising approach for effective cancer treatment.Entities:
Keywords: CC49 monoclonal antibody; Combined therapy; Hyperthermia; Nano-brachytherapy; Nano-radiopharmaceuticals; Radionuclide ((131)I) therapy; Superparamagnetic nanoparticles
Mesh:
Substances:
Year: 2020 PMID: 32681867 DOI: 10.1016/j.ijpharm.2020.119628
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875